Impacto intraoperatorio de la ultrafiltración modificada en pacientes pediátricos sometidos a cirugía cardíaca con circulación extracorpórea

Curi-Curi, Pedro; Villar, María Rashidi Springall del; Gómez-García, Lorena; Vergara, Beatriz González; Calderón‐Colmenero, Juan; Ramírez-Marroquín, Samuel; Cervantes-Salazar, Jorge

doi:10.1016/j.circv.2016.02.003

Cited by 2 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the results of this study [34], we can say that although the baseline concentrations of IL-6 in the patients of the problematic group were higher in relation to those of the control group, the removal of this pro-inflammatory agent by MUF was statistically significant. This indicates that MUF is a procedure that can benefit pediatric patients with congenital heart disease undergoing CPB because it is able to decrease the concentration of IL-6.…”

Section: Resultsmentioning

confidence: 59%

Impact of Modified Ultrafiltration in Congenital Heart Disease Patients Treated with Cardiopulmonary Bypass

Curi-Curi¹,

Alanis²,

Colmenero³

et al. 2018

Congenital Heart Disease

Self Cite

View full text Add to dashboard Cite

Modified ultrafiltration is used in cardiac surgery with cardiopulmonary bypass in order to diminish systemic inflammatory response syndrome. We aimed to show its utility for removing pro-inflammatory agents in operated pediatric patients with congenital heart disease and its impact at operative care. A clinical case control trial was designed, including patients with simple congenital heart disease operated on with cardiopulmonary bypass in a 1-year period. We randomized them to a problematic group (with modified ultrafiltration, n = 15) and a control group (without it, n = 16), and blood samples to measure interleukins (6 and 10), 3d and 4d complement fraction concentrations were taken at the following times: baseline, before cardiopulmonary bypass, after it, after modified ultrafiltration, and from the ultrafiltration concentrate. Operative clinical end points of success were defined as hemodynamic stability, absence of morbidity, and lack of mortality. We observed a higher significant interleukin six concentration in the problematic group patients at baseline, as well as a higher removal of this pro-inflammatory agent at the ultrafiltration concentrate. Modified ultrafiltration has a positive impact over simple congenital heart disease surgery with cardiopulmonary bypass because of removing interleukin 6. We recommend its routinely use when hemodynamic conditions are favorable.

show abstract

Section: Resultsmentioning

confidence: 59%

Impact of Modified Ultrafiltration in Congenital Heart Disease Patients Treated with Cardiopulmonary Bypass

Curi-Curi¹,

Alanis²,

Colmenero³

et al. 2018

Congenital Heart Disease

Self Cite

View full text Add to dashboard Cite

show abstract

“…Based on the results of this study [34], we can say that although the baseline concentrations of IL-6 in the patients of the problem group were higher in relation to those of the control group, the removal of this pro-inflammatory agent by MUF was statistically significant. This indicates that MUF is a procedure that can benefit pediatric patients with congenital heart disease undergoing CPB because it is able to decrease the concentration of IL-6.…”

Section: Resultsmentioning

confidence: 60%

Utility of Modified Ultrafiltration in Congenital Heart Disease Patients Operated with Cardiopulmonary Bypass

Curi-Curi¹,

Calderón‐Colmenero²,

Marroquín³

et al. 2019

Advances in Extra-Corporeal Perfusion Therapies

Self Cite

View full text Add to dashboard Cite

Modified ultrafiltration is used in cardiac surgery with cardiopulmonary bypass in order to diminish systemic inflammatory response syndrome. We aimed to show its utility for removing pro-inflammatory agents in operated pediatric patients with congenital heart disease and its impact at operative care. A clinical case-control trial was designed, including patients with simple congenital heart disease operated on with cardiopulmonary bypass in a 1-year period. We randomized them to a problem group (with modified ultrafiltration, n = 15) and a control group (without it, n = 16), and blood samples to measure interleukins (6 and 10); 3d and 4d complement fraction concentrations were taken at the following times: baseline, before cardiopulmonary bypass, after it, after modified ultrafiltration, and from the ultrafiltration concentrate. Operative clinical end points of success were defined as hemodynamic stability, absence of morbidity, and lack of mortality. We observed a higher significant interleukin 6 concentration in the problem group patients at baseline, as well as a higher removal of this pro-inflammatory agent at the ultrafiltration concentrate. Modified ultrafiltration has a positive impact over simple congenital heart disease surgery with cardiopulmonary bypass because of removing interleukin 6. We recommend its routine use when hemodynamic conditions are favorable.

show abstract

Impacto intraoperatorio de la ultrafiltración modificada en pacientes pediátricos sometidos a cirugía cardíaca con circulación extracorpórea

Cited by 2 publications

References 35 publications

Impact of Modified Ultrafiltration in Congenital Heart Disease Patients Treated with Cardiopulmonary Bypass

Impact of Modified Ultrafiltration in Congenital Heart Disease Patients Treated with Cardiopulmonary Bypass

Utility of Modified Ultrafiltration in Congenital Heart Disease Patients Operated with Cardiopulmonary Bypass

Contact Info

Product

Resources

About